Costly sequential experimentation and project valuation with an application to health technology assessment

Journal of Economic Dynamics and Control

Volumn 77, Issue , 2017, Pages 202-229

  Thijssen, Jacco J J ^a   Bregantini, Daniele ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

Author keywords

Health technology assessment; Optimal stopping; Sequential experimentation

Indexed keywords

EID: 85015970099     PISSN: 01651889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jedc.2017.01.016     Document Type: Article

References (48)

1. Arlotto, A., Chick, S., Gans, N., Optimal hiring and retention policies for heterogeneous workers who learn. Manag. Sci. 60:1 (2014), 110–129.
2. Armitage, P., Sequential Medical Trials, 1975, Blackwell, Oxford.
3. Bergemann, D., Valimaki, J., Bandit Problems, 2006, Cowles Foundation, 1–16 discussion paper No 1551.
4. Berry, D., Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat. Med. 4 (1985), 521–526.
5. Berry, D., Bayesian clinical trials. Nat. Rev. Drug Discov. 5 (2006), 27–36.
6. Bolton, P., Harris, C., Strategic experimentation. Econometrica 67:2 (1999), 349–374.
7. Borodin, A., Salminen, P., Handbook of Brownian Motion – Facts and Formulae, second edition, 2002, Birkhäuser Verlag, Basel.
8. Chick, S., Forster, M., Pertile, P., 2015. A Bayesian-Theoretic Model of Sequential Experimentation with Delayed Response. DERS Discussion Paper 15/09, University of York.
9. Claxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., Hinde, S., Devlin, N., Smith, P., Sculpher, M., Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol. Assess., 19(14), 2015.
10. Close, A., Robertson, C., Rushton, S., Shirley, M., Vale, L., Ramsay, C., Pickard, R., Comparative cost-effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of men with localised prostate cancer: A health technology assessment from the perspective of the UK national health service. Eur. Urol. 64 (2013), 361–369.
11. Dayanik, S., Karatzas, I., On the optimal stopping problem for one-dimensional diffusions. Stoch. Process. Appl. 107 (2003), 173–212.
12. Dixit, A., Pindyck, R., Investment Under Uncertainty, 1994, Princeton University Press, Princeton.
13. Draper, D., Discussion of the paper by Hampson and Jennison. J. R. Stat. Soc. B, 75, 2013, 48.
14. Driffield, T., Smith, P., A real option approach to watchful waiting: theory and illustration. Med. Dec. Mak. 27 (2007), 178–188.
15. FDA, 2006. Fast Track Drug Development Programs Designation, Development, and Application Review. U.S department of Health and Human Services, Food and Drug administration.
16. FDA, 2010. Adaptive Design Clinical Trials for Drugs and Biologics. U.S department of Health and Human Services, Food and Drug administration.
17. FDA, 2013. Expedited Programs for Serious Conditions Drugs and Biologics. U.S department of Health and Human Services, Food and Drug administration.
18. Forster, M., Pertile, P., Optimal decision rules for HTA under uncertainty: a wider, dynamic perspecitve. Health Econ. 22 (2013), 1507–1514.
19. Hampson, L., Jennison, C., Group sequential tests for delayed responses. J. R. Stat. Soc. B 75 (2013), 3–54.
20. Heiodhues, P., Rady, S., Strack, P., Strategic experimentation with private payoffs. J. Econ. Theory 159 (2015), 531–551.
21. Jovanovic, B., Job search and the theory of turnover. J. Polit. Econ. 87 (1979), 972–990.
22. Keller, G., Rady, S., Strategic experimentation with poisson bandits. Theor. Econ. 5 (2010), 275–311.
23. Keller, G., Rady, S., Cripps, M., Strategic experimentation with exponential bandits. Econometrica 73:1 (2005), 39–68.
24. Kwon, H., Lipmann, S., Acquisition of project-specific assets with Bayesian updating. Oper. Res. 59 (2011), 1119–1130.
25. Meltzer, D., Smith, P., Theoretical issues relevant to the economic evaluation of health technologies. Pauly, M., Mcguire, T., Barros, P., (eds.) Handbook of Health Economics, vol.2, 2012, Elsevier, Amsterdam, 433–469.
26. Mikhalevich, V., Bayeisan choice between two hypotheses for the mean value of a normal process. Visnik Kiiv. Univ. 1 (1958), 101–104 In Ukranian.
27. Montazerhodjat, V., Lo, A., 2015. Is the FDA Too Conservative of Too Aggressive ? A Bayesian Decision Analysis of Clinical Trial Design. NBER working paper 21499.
28. Moscarini, G., Smith, L., The optimal level of experimentation. Econometrica 69 (2001), 1629–1644.
29. Myers, S., Determinants of corporate borrowing. J. Financial Econ. 5 (1977), 147–176.
30. Øksendal, B., Optimal stopping with delayed information. Stoch. Dyn. 5 (2004), 271–280.
31. Øksendal, B., Stochastic Differential Equations, fifth edition, 2010, Springer, New York.
32. Øksendal, B., Sulem, A., Applied Stochastic Control of Jump Diffusions, second edition, 2007, Springer–Verlag, Berlin.
33. Palmer, S., Smith, P., Incorporating option value into the economic evaluation of health care technologies. J. Health Econ. 19 (2000), 755–766.
34. Pertile, P., Forster, M., LaTorre, D., Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies. J. R. Stat. Soc. A 177 (2014), 419–438.
35. Peskir, G., Shiryaev, A., Optimal Stopping and Free Boundary Problems, 2006, Birkhäuser Verlag, Basel.
36. Poor, V., Hadjiliadis, O., Quickest Detection, 2009, Cambridge University Press, Cambridge.
37. Ramsey, S., Wilkie, R., Briggs, A., Brown, R., Buxton, M., Chawla, A., Cook, J., Glick, H., Petitti, D., Reed, S., Good research practices for cost-effectivness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. Value in Health 8:5 (2005), 521–533.
38. Rothschild, M., Two armed bandit theory of market pricing. J. Econ. Theory 9 (1974), 185–202.
39. Samsa, G., Edelman, D., Rothman, M., Williams, G., Lipscomb, J., Matchar, D., Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 15 (1999), 141–155.
40. Shiryaev, A., On two problems of sequential analysis. Kibernetika 2 (1967), 79–80.
41. Shiryaev, A., Optimal Stopping Rules, 1978, Springer–Verlag, Berlin.
42. Spiegelhalter, D., Abrams, K., Myles, J., Bayesian Approaches to Clinical Trials and Health-Care Evaluation, 2004, John Wiley & Sons, New York.
43. Steele, J., Stochastic Calculus and Financial Applications, 2001, Springer–Verlag, New York.
44. Stokey, N., The Economics of Inaction, 2009, Princeton University Press, Princeton.
45. Sundaram, R., Generalized Bandit Problems, 2005, Springer–Verlag, Berlin.
46. Wald, A., Sequential Analysis, 1947, John Wiley & Sons, London.
47. William, A., Pinto, E., The value of information and optimal clinical trial design. Stat. Med. 24 (2005), 1791–1806.
48. YHEC, 2009. Organisational and Behavioural Barriers to Medical Technology Adoption. Report by York Health Economics Consortium for NHS Institute for Innovation and Improvement.